53542-U
Ascentis® Express Peptide 160 Å ES-C18 (2.7 μm) HPLC Columns
L × I.D. 5 mm × 4.6 mm, HPLC Guard Cartridge, pkg of 3 ea
Synonym(s):
Superficially Porous Wide Pore C18 Guard Column
Sign In to View Organizational & Contract Pricing
Select a Size
About This Item
UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
Product Name
Ascentis® Express Peptide ES-C18, 2.7 μm Guard Cartridge, 2.7 μm particle size, L × I.D. 5 mm × 4.6 mm, pkg of 3 ea
material
stainless steel column
Quality Level
Agency
suitable for USP L1
product line
Ascentis®
feature
endcapped: no
packaging
pkg of 3 ea
extent of labeling
4.6% carbon loading
technique(s)
HPLC: suitable
LC/MS: suitable
UHPLC-MS: suitable
UHPLC: suitable
L × I.D.
5 mm × 4.6 mm
surface area
90 m2/g
matrix
superficially porous particle
matrix active group
C18 (octadecyl) phase
particle size
2.7 μm
pore size
160 Å
operating pH
1-9
separation technique
reversed phase
Looking for similar products? Visit Product Comparison Guide
Related Categories
General description
Ascentis Express Guard Columns provide physical (filtration) and chemical protection for costly analytical columns without compromising the very high performance of Ascentis Express columns. These Ascentis Express guard columns are capable of continuous use at pressures up to 9000 psi (600 bar) with only hand-tightening. Guard cartridges are easily replaced without removing the guard column holder from the flow path. The cartridges are packed with Ascentis Express Fused-Core®particles. Order guard column holder (53500-U) separately.
Application
- Proteotypic Peptide Identification in Biosynthetic Insulin: Utilizes Ascentis® Express Peptide ES-C18, 2.7 μm Guard Cartridge in multiplexed targeted mass spectrometry to identify proteotypic tryptic peptides of recombinant human insulin and biosynthetic insulin analogues, demonstrating high resolution and precision in peptide mapping essential for biopharmaceutical analysis (Qasem et al., 2019).
- Preclinical Pharmacokinetic Study of Thymopentin: Employs the Ascentis® Express Peptide ES-C18, 2.7 μm Guard Cartridge for the high-resolution separation and quantitative determination of thymopentin in beagle dog blood, highlighting its application in pharmacokinetic studies and drug development (Shi et al., 2015).
- Cytochrome P450 and UDP-Glucuronosyltransferases Quantification: Features the use of Ascentis® Express Peptide ES-C18, 2.7 μm Guard Cartridge in a targeted proteomics approach for the absolute quantification of clinically relevant enzymes, offering insights into protein expression levels critical for drug metabolism and pharmacogenomics studies (Gröer et al., 2014).
- Carotenoid Analysis in Superficially Porous Phases: Demonstrates the capability of the Ascentis® Express Peptide ES-C18, 2.7 μm Guard Cartridge in extending the carotenoid test to new stationary phases, underlining its versatility and effectiveness in analytical chromatography for complex natural products (Lesellier, 2012).
Legal Information
Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany
Fused-Core is a registered trademark of Advanced Materials Technology, Inc.
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Meiyun Shi et al.
Journal of separation science, 38(8), 1351-1357 (2015-01-30)
The pentapeptide thymopentin (Arg-Lys-Asp-Val-Tyr, RKDVY) corresponds to amino acids 32-36 of the 49 amino acid immunomodulatory polypeptide, thymopoietin, whose biological activity is partially reproduced. Thymopentin is widely used in the clinic and represents a promising target for drug design but
E Lesellier
Journal of chromatography. A, 1266, 34-42 (2012-11-03)
The recent introduction of new stationary phases for liquid chromatography based on superficially porous particles, called core-shell or fused-core, dramatically improved the separation performances through very high efficiency, due mainly to reduced eddy diffusion. However, few studies have evaluated the
C Gröer et al.
Journal of pharmaceutical and biomedical analysis, 100, 393-401 (2014-09-15)
Cytochrome P450 (CYP) enzymes and UDP-glucuronosyltransferases (UGT) are major determinants in the pharmacokinetics of most drugs on the market. To investigate their impact on intestinal and hepatic drug metabolism, we developed and validated quantification methods for nine CYP (CYP1A2, CYP2B6
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service